OMAX Stock Overview
Develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Vivesto AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 0.022 |
| 52 Week High | SEK 0.041 |
| 52 Week Low | SEK 0.016 |
| Beta | 0.55 |
| 1 Month Change | 14.14% |
| 3 Month Change | 5.31% |
| 1 Year Change | -43.81% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -98.88% |
Recent News & Updates
Recent updates
Shareholder Returns
| OMAX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 3.3% | -2.9% | -2.6% |
| 1Y | -43.8% | -14.7% | 6.9% |
Return vs Industry: OMAX underperformed the German Biotechs industry which returned -14.7% over the past year.
Return vs Market: OMAX underperformed the German Market which returned 6.9% over the past year.
Price Volatility
| OMAX volatility | |
|---|---|
| OMAX Average Weekly Movement | 22.1% |
| Biotechs Industry Average Movement | 6.8% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 11.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: OMAX's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: OMAX's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1988 | 4 | Erik Kinnman | www.vivesto.com |
Vivesto AB develops, produces, markets, and sells drugs in the field of human and veterinary oncology in Sweden. Its lead product is Apealea (paclitaxel micellar) for the treatment of ovarian cancer. The company’s products portfolio includes Docetaxel micellar, a patented formulation that combines cytotoxin docetaxel with XR-17, which is in Phase 1b clinical trial for the treatment of prostate cancer; and Cantrixil to treat ovarian cancer.
Vivesto AB Fundamentals Summary
| OMAX fundamental statistics | |
|---|---|
| Market cap | €13.14m |
| Earnings (TTM) | -€8.12m |
| Revenue (TTM) | €574.69k |
22.9x
P/S Ratio-1.6x
P/E RatioIs OMAX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| OMAX income statement (TTM) | |
|---|---|
| Revenue | SEK 6.61m |
| Cost of Revenue | SEK 0 |
| Gross Profit | SEK 6.61m |
| Other Expenses | SEK 100.02m |
| Earnings | -SEK 93.40m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 20, 2025
| Earnings per share (EPS) | -0.17 |
| Gross Margin | 100.00% |
| Net Profit Margin | -1,412.63% |
| Debt/Equity Ratio | 0% |
How did OMAX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/22 00:23 |
| End of Day Share Price | 2024/12/20 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Vivesto AB is covered by 6 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Camilla Oxhamre | Carnegie Investment Bank AB |
| Susie Jana | Edison Investment Research |
| Sean Conroy | Edison Investment Research |